Class III — Low Risk

Low risk — use of or exposure to this product is not likely to cause adverse health consequences.

Quantikine IVD Erythropoietin Human Serum Controls for use as quantitative Recalled by R & D Systems, Inc. Due to The Instructions for Use (IFU, Part Number 750095)...

Date: June 14, 2022
Company: R & D Systems, Inc.
Status: Ongoing
Source: FDA (Device)

What You Should Do

Stop using this product immediately. Do not consume, use, or distribute it.

Return the product to the place of purchase for a full refund. If you have questions, contact R & D Systems, Inc. directly.

Affected Products

Quantikine IVD Erythropoietin Human Serum Controls for use as quantitative controls for the determination of Erythropoietin concentrations in human serum and plasma. IFU, Part Number 750095

Quantity: 400

Why Was This Recalled?

The Instructions for Use (IFU, Part Number 750095) provided with the affected lots by the firm contains an error associated with product s CE marking. The CE mark contained in the IFU is followed by the Notified Body designation, British Standards Institution number 2797 (BSI-2797) for product inserts 750095.28 and 750095.29. The erroneous label CE2797 were in the IFU insert revision 750095.28 for the 408 affected lots that were shipped. No product was packed with erroneous insert revision 750095.29. Since the product is currently CE marked as a Class I - self-certified product under the EU In Vitro Diagnostics Directive, the Notified Body designation should not be specified. As part of the corrective action, the firm has notified the customers who received the products with erroneous labeling, and is conducting the replacements with the correct product insert containing the Insert Revision 750095.30

Where Was This Sold?

This product was distributed nationwide across all 50 states.

Affected (51 states)Not affected

About R & D Systems, Inc.

R & D Systems, Inc. has 6 total recalls tracked by RecallDetector.

Related Recalls

Data sourced from the FDA (Device). Last updated March 26, 2026. View original report